Evidence map›Paper›PMID 23671401›Full record

ArticleReviews in urology2013

The other bladder syndrome: underactive bladder.

Minoru Miyazato, Naoki Yoshimura, Michael B Chancellor

2 registry-linked trialsAbstract read
In one paragraph

Article in Reviews in urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04161183 nacompletednot on this mapstarted 2019, after this paper: background citation

Extracoporeal Shock Wave Therapy (ESWT) for the Treatment of Detrusor Underactivity/ Underactive Bladder (DU/UAB) - a Single Center, Randomized, Double-blind, Placebo-controlled, Prospective Study

TypeinterventionalSponsorChang Gung Memorial HospitalRan2019 to 2022Enrolled11ConditionsDetrusor, Underactive, Detrusor UnderactivityArmsExtracoporeal shock wave therapy, Placebo
NCT04516434 nacompletednot on this mapstarted 2021, after this paper: background citation

AMPLIFY: Amplifying Sensation in Underactive Bladder

TypeinterventionalSponsorDuke UniversityRan2021 to 2024Enrolled20ConditionsUrinary Bladder, UnderactiveArmsNeurometer Neurotron CPT, Cystometry, Pressure-flow study
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 146 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Minoru Miyazato
Naoki Yoshimura
Michael B Chancellor

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detrusor underactivity, or underactive bladder (UAB), is defined as a contraction of reduced strength and/or duration resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying within a normal time span. UAB can be observed in many neurologic conditions and myogenic failure. Diabetic cystopathy is the most important and inevitable disease developing from UAB, and can occur silently and early in the disease course. Careful neurologic and urodynamic examinations are necessary for the diagnosis of UAB. Proper management is focused on prevention of upper tract damage, avoidance of overdistension, and reduction of residual urine. Scheduled voiding, double voiding, al-blockers, and intermittent self-catheterization are the typical conservative treatment options. Sacral nerve stimulation may be an effective treatment option for UAB. New concepts such as stem cell therapy and neurotrophic gene therapy are being explored. Other new agents for UAB that act on prostaglandin E2 and EP2 receptors are currently under development. The pharmaceutical and biotechnology industries that have a pipeline in urology and women's health may want to consider UAB as a potential target condition. Scientific counsel and review of the current pharmaceutical portfolio may uncover agents, including those in other therapeutic fields, that may benefit the management of UAB.

Indexed as

Detrusor overactivityDiabetic cystopathyOveractive bladderUnderactive bladder

Identifiers

PMID23671401
PMCPMC3651538
OpenAlexW141945770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.